#### Calculating and Using Probability-Weighted Multiples (PWM)

Presented by Joe Gatto to Tech Coast Angels September 19, 2019

This ppt and spreadsheet are now on Flock: TCA-SD Education Committee Which of these deals, would you invest in?

Deal 1	Deal 2	Deal 3
100x	<b>16x</b>	8x
10%	30%	50%
0x	Ox	Ox
90%	70%	50%



Which deal represents the "average" TCA deal?

#### Agenda

- Data from TCA exits
- Calculating Probability-Weighted Multiples (PWM)
  - For Tech
  - For Biotech
- Portfolio-implications of TCA-exit data
- Personal conclusions
- Q&A

#### TCA's past investments have averaged 4.9x return!

If you had invested \$25k into each of the 182 TCA deals that are shutdown or exited, you would have:

- Invested \$4.6m
- Returned \$22.4m (4.9x)

If you had sold MindBody and GreenDot at their IPOs, your return would have only 14.4m(3.2x)

Source: TCA Portfolio Analysis, July 2019, John Harbison

However, returns were driven by 3 home runs. If you missed those 3, your return was only 1.4x. 1.6% of deals produced 71% of returns



#### 125 of 182 deals (69%) lost money. 3(1.6%) > 100x.



#### Analysis of angel-investment opportunities should:

Be grounded in the reality of past-deal statistics

- "This deal is like the other 182"
- 69% chance of losing money

and

Allow you to have deal-specific judgments

- "This deal is different"
- Total Addressable Market size (TAM)
- Demonstrated product-market fit
- Deal price
- Future dilution needed
- Management's ability to scale
- IP/Competition

### I use a tree to describe the range of outcomes and to calculate expected return (PWM) for AwesomeCo

	\$1m raise	Post						Future	
	on	Val (\$m)				TAM (\$m)	Exit Mult	Dilution	
	\$9m pre	10.0				2,000	5	40%	
				Ν	Market	Revenue	Exit		PW
				Prob	Share	(\$m)	Value	MOIC	MOIC
			King	0.7%	35%	700	3,500	210	1.4
			10%	_					
		Mass Mkt	Prince	2.0%	10%	200	1,000	60	1.2
	Cross	25%	30%	_					
	Chasm		Serf	4.0%	3%	60	300	18	0.7
Early	40%	· 18	60%	_					
Success		Niche Only		20.1%		30	150	9	1.8
67%		75%							
	No cross			40.2%	0%	0	0	0	0.0
	60%								
Early Fail				33.0%	0%	0	0	0	0.0
33%				100.0%	0.6%				5.1
							ooking fo	r > 10x	

#### This baseline tree comports with past stats: About 70% chance of loss. "Expected" 5.1x return.

	\$1m raise	Post						Future	
	on	Val (\$m)				TAM (\$m)	Exit Mult	Dilution	
	\$9m pre	10.0				2,000	5	40%	
				Γ	/larket	Revenue	Exit		PW
				Prob	Share	(\$m)	Value	MOIC	MOIC
			King	0.7%	35%	700	3,500	210	1.4
			10%						
		Mass Mkt	Prince	2.0%	10%	200	1,000	60	1.2
	Cross	25%	30%						
	Chasm		Serf	4.0%	3%	60	300	18	0.7
Early	40%		60%						
Success		Niche Only		20.1%		30	150	9	1.8
67%		75%	2	$\nabla \nabla$	1				
	No cross		7	40.2%	0%	0	0	0	0.0
	60%		7		$\leq$				
Early Fail			7	33.0%	0%	0	0	q	10.0
33%				100.0%	0.6%			2	5.1
								レ	



- Early Success
  - Reach ~ \$200k (non-trial, non-pilot) annual revenue
  - Default probability 67%; however, set to 100% if already reached

33%

- Cross Chasm
  - Reach  $\sim$  \$20m ARR
  - Default probability 40% (given Early Success)
    - Gently increase for rock star, full team; high ARR; high growth
- Mass Market
  - Reach  $\sim$  \$100m ARR
  - Default probability 25% (given Crossed Chasm). Rarely adjust.

#### Mass-Market Share Approach

10 major competitors (83% share) + niche players (17%)

- Equally likely that AwesomeCo becomes one of the 10 majors
- 1 King (35% share) (1/10 or 10% probability)
- 3 Princes (10% share each, 30% total) (3/10, or 30% probability)
- 6 Serfs (3% share each, 18% total) (6/10, or 60% probability)



#### Market share approach can be tailored to market

• Some markets are more or less consolidated >>

• AwesomeCo's

		Consolidated	Typical	Fragmented
Some markets are	# MM Competitors	5	10	20
	# King	1	1	2
more or less	% Share per King	50%	35%	15%
consolidated >>	Tot Share of Kings	50%	35%	30%
consolidated >>	# Princes	1	3	6
	% Share per Prince	20%	10%	4%
	Tot Share of Princes	20%	30%	24%
	# Serfs	3	6	12
	% Share per Serf	7%	3%	2%
	Tot Share of Serfs	21%	18%	24%
	Share MM Players	91%	83%	78%
	Share Niche Players	9%	17%	22%
AwesomeCo's	Tot Share (MM+Nicl	100%	100%	100%
chances (given MM				
	King Chance	20%	10%	10%
success) >>	Prince Chance	20%	30%	30%
	Serf Chance	60%	60%	60%
	State Contractor	100%	100%	100%

#### TAM: focus on Sweet Spot market

- SS might include ex-US, often not
- SS might include follow-on products, usually not
- MUST align with your Market Share numbers
  - If they become King, could they really get 35% of *this* TAM
- Use TAM 5 7 years from now (if growth is believable)
- Mechanodontics: 10m cases/yr \* \$1,500/case = \$15b
- Habitu8: 125m corporate desktops \* \$24/yr = \$3b

#### Case Study: Habitu8

- \$800k ARR for product 1. LOIs for product 2.
- CEO co-founded co that IPO'd for \$900m. Eng+Sales

	\$.75m raise on \$6m pre	Post Val (\$m) 6.75				TAM (\$m) 3,000	Exit Mult 5	Future Dilution 45%	
					Market	Revenue	Exit		PW
				Prob	Share	(\$m)	Value	MOIC	MOIC
Valuation T	ree for Habi	tu8							
			King	1.1%	35%	1,050	5,250	428	4.5
			10%						
		Mass Mkt	Prince	3.2%	10%	300	1,500	122	3.9
	Cross	25%	30%						
	Chasm		Serf	6.4%	3%	90	450	37	2.3
Early	50%		60%						
Success		Niche Only		31.9%		30	150	12	3.9
85%		75%		_					
	No cross			42.5%	0%	0	0	0	0.0
	50%			_					
Early Fail				15.0%	0%	0	0	0	0.0
15%				100.0%	0.9%				14.7

#### Case study: Mechanodontics (now Brius)

							Future	
Post					TAM (\$m)	Exit Mult	Dilution	
\$11.5m					15,000	5	75%	
				Market	Revenue	Exit		PW
			Prob	Share	(\$m)	Value	MOIC	MOIC
		King	0.5%	20%	3,000	15,000	326	1.8
		5%	-8					
	Mass Mkt	Prince	3.3%	10%	1,500	7,500	163	5.3
	33%	30%						
Cross Chasm		Serf	7.1%	3%	450	2,250	49	3.5
33%		65%						
	Niche Only		22.1%	0.2%	30	150	3	0.7
	67%		-					
No cross			67.0%	0%	0	0	0	0.0
67%			100.0%					11.3

Case Study for ??? (real company pitched TCA)

- TAM: 600k shops \* \$2k/yr = \$1.2b
- Had \$600k ARR from 1000 shops. Team of 16 FTEs.
- Had reached CF breakeven. Wanted \$ to speed growth.

	\$1m raise on \$3.5m pre	Post Val (\$m) 4.5				TAM <mark>(</mark> \$m) 1,200	Exit Mult 5	Future Dilution 25%	
Valuation T	ree for ???			Prob	Market Share	Revenue (\$m)	Exit Value	MOIC	PW MOIC
			King	1.3%	35%	420	2,100	350	4.4
			10%						
		Mass Mkt	Prince	3.8%	10%	120	600	100	3.8
-	Cross Chasm	25%	30% Serf	7.5%	3%	36	180	30	2.3
Early	50%		60%				150		
Success		Niche Only		37.5%		30	150	25	9.4
100%		75%							
	No cross			50.0%	0%	0	0	0	0.0
	50%								
Early Fail				0.0%	0%	0	0	0	0.0
0%				100.0%	1.0%				19.8

MindBody was TCA's most profitable deal: 264x

- TAM: 600k shops \* \$2k/yr = \$1.2b
- Had \$600k ARR from 1000 shops. Team of 16 FTEs.
- Had reached CF breakeven. Wanted \$ to speed growth.

	\$1m raise on \$3.5m pre	Post Val (\$m) 4.5				TAM (\$m) 1,200	Exit Mult 5	Future Dilution 25%	
					Market	Revenue	Exit		PW
Valuation T	ree for 222			Prob	Share	(\$m)	Value	MOIC	MOIC
valuation			King	1.3%	35%	420	2,100	350	4.4
		Maga Milit	10%	2.00/	100/	120	600	100	2.0
	Cross	25%	30%	3.8%	10%	120	600	100	3.8
	Chasm		Serf	7.5%	3%	36	180	30	2.3
Early	50%		60%						
Success		Niche Only		37.5%		30	150	25	9.4
100%		75%							
	No cross			50.0%	0%	0	0	0	0.0
	50%								
Early Fail				0.0%	0%	0	0	0	0.0
0%				100.0%	1.0%				19.8

# This core idea (start by understanding base rates, then adjust) can be applied to **biotech** as well.

- "POA", or Probability of Approval, is the Probability of success from phase 1 through to approval
- POAs range by therapeutic area
  - − Overall: 10 − 15%
  - 4% for cancer

### I decomposed overall POA of 12% into chances for "Safe", "Effective", and "Execute"

- Safe: is the toxicity level acceptable for approval?
- Effective: will it work well enough to be approved?
- Execute: raise enough funding, execute trials well?
- Lack of efficacy is more common failure than toxicity
- This tree is for IND-approved therapy about to start ph1
  - For a *pre*-IND therapy, add a branch at left for chance of IND



#### I relied on these sources for success/failure rates:

- "Clinical development success rates for investigational drugs" Hay, et al., *Nature Biotechnology* Jan 2014
- "Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results" Hwang et al, *JAMA Internal Medicine*, Oct 2016
- Clinical Development Success Rates 2006-2015 Thomas (BiomedTracker), et al.
- Estimation of clinical trial success rates and related parameters" Wong et al., *Biostatistics* (2019)

#### Biotech case study—A real company I analyzed

- Efficacy: demonstrations of efficacy (directly in pigs and indirectly in humans) was very compelling. Theory and MOA seemed very solid. I increased p(Effective) from base rate of 25% to 75% (probably *too* much)
- Safety: shown safe in pigs, but no long-term tests. Naturally occurring in humans, but some possibility of immunogenicity due to donor sourcing. I used default p(Safety) of 60%
- **Execution**: the more I communicated with CEO, the less confident I became. I dug deep into market size and surmised that they were off by 10x for this orphan indication. I dropped p(Execute) from base rate of 80% to 60%

# The PWM calculated to 8.2. Even that felt high. I passed.

								Dilution	
raise	\$2.5	Post						Through	
convert	\$0.0	Val (\$m)			2	TAM (\$m)	Exit Mult	Phase3	
pre	\$9.0	<b>11.5</b>				880	5	70%	
					Market	Revenue	Exit		PW
				Prob	Share	(\$m)	Value	MOIC	MOIC
			Leader	8.9%	55%	484	2 4 2 0	63	5.6
			33%	0.570	3370	404	2,420	00	5.0
		Execute	Niche	8.9%	25%	220	1,100	29	2.6
		60%	33%			220	1)100	20	210
	Effective		Inferior	9.2%	0%	0	0	0	0.0
	75%		34%						
Safe		No		18.0%	0%	0	0	0	0.0
60%		40%							
	No			15.0%	0%	0	0	0	0.0
	25%								
No				40.0%	0%	0	0	0	0.0
40%		27%		100.0%	7.1%				8.2
		p(approval)							

#### Avoid "garbage in garbage out" Avoid "undue optimism". Undue optimism is...

- Expecting your personal-success probability to be inappropriately higher than what the statistics would warrant
- Like giving *this* coin a 75% chance of heads because you really did due diligence on this coin and you have a really good feeling about the team that handed you this coin
- Like giving *this* coin a 75% chance of heads because it would be really great for the world if this coin turned out heads

### Many angel studies point to 25% - 30% IRR; however, 50% - 70% of deals lose money

- Harbison (2019) 182 TCA deals
  - 69% lost money, 4.9x, 1.6% of deals provided 71% of returns
- Villalobos & Payne (2007) 117 "TCA" deals
  - 68% lost money, 5x overall return
- Wiltbank and Boeker (2007) 3,097 angel investments
  - 52% lost money, 7% of deals returned greater than 10x, 30% IRR

### TCA $\Rightarrow$ had a %-strikeouts in line with the worst VC funds, but overall return of best funds



### Successful funds have more "home run" investments (defined as investments that return >10x) TCA had 11/182 or 6% home runs (>10x) $\Rightarrow$



#### Great funds have home runs of greater magnitude. TCA's average homerun was 68x



#### Portfolio Construction Implications

If 1.6% of TCA deals are outliers, and yield 71% of returns, it is <u>critical</u> to have at least one outlier in your portfolio.

How many deals did it take to get > 50% chance of outlier?



#### It took 45 investments to get 50% chance of outlier



Assuming 1.6% of deals are outliers (>100x)

## You would have needed a portfolio of 45 deals to achieve a 50-50 chance of 4x portfolio return

MEDIAN of 10,000 portfolios constructed randomly from TCA's 182 exited deals



## 40 deals gave you 50% chance of 3x☆80 deals gave you 70% chance of 3x☆



#### Personal conclusions I plan to employ:

- Be realistic and explicit about chance of failure
- Build a tree and calculate PWM for each deal
- Only invest when PWM is a believable 10x or better
- Continue to grow my portfolio to 50 deals or more
- To do that, I need to stretch my capital
  - Reduce my typical check size to \$25k
  - Generally avoid follow-ons

#### Questions?

Joe Gatto joe@joegatto.com in/joegatto1

Acknowledgments and thanks! to :

- John Harbison, TCA, data on 182 TCA outcomes
- Clint Korver, Ulu Ventures, Crossing the Chasm tree approach